Metatissue

• Tunable hydrogels with controllable stiffness and gelation time
• High reproducibility across batches and applications
• Ready-to-use and easy-to-handle product formats
• Strong foundation in academic research and validation
• Cost-effective solutions that reduce failed clinical candidates
• Facilitates seamless adoption across established research pipeline
• Designed for interoperable integration into standardized workflows

Specialising in the design and manufacturing of xeno-free hydrogels, bioactive scaffolds, and bioinks, Metatissue® provides solutions that closely mimic physiological microenvironments. These platforms support a wide range of applications, including disease modelling, drug discovery, tissue engineering, and personalized medicine.

Metatissue®’s technology addresses one of the major challenges in preclinical research: the lack of reliable human-relevant models. By offering human-based biomaterials derived from ethically sourced proteins, the company enables researchers to generate more accurate data, ultimately improving the success rate of clinical trials.

A key advantage of Metatissue’s platforms is their potential to significantly reduce, or even replace, the use of animal models in pre-clinical screening. This not only accelerates research timelines and reduces costs but also supports ethical research practices and ultimately also aids regulatory overview.